Initial evidence for the efficacy of supplementing incretin activity in patients with T2DM came from short-term experiments in which exogenous, native GLP-1 was administered by continuous intravenous (IV) or subcutaneous (SC) infusion. This evidence concerns the gene GCG and type 2 diabetes mellitus.